Gain Therapeutics GANX Income Statement (2020-2026)

NASDAQ GANX
$1.71 -0.01 (-0.58%)
At close: Sep 10, 2026 · 4:00 PM EDT
Reported Financials

Gain Therapeutics Quarterly Income Statement

Periods 26 quarters
Latest Jun 2026

Gain Therapeutics reported net income of -$4.68M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
11.88M11.88M11.88M11.88M11.88M11.88M12.09M12.63M12.78M13.01M18.04M19.22M25.96M27.13M28.75M30.77M35.98M32.97M42.49M43.34M
Revenue & cost
Revenue
0.03M0.04M0.05M0.10M0.06M
Operating items
Research & DevelopmentR&D
2.48M1.47M1.56M2.58M1.96M2.27M2.79M3.99M2.37M2.37M2.51M4.44M2.62M1.22M2.26M2.76M2.85M2.35M2.76M2.14M
Selling, General & AdministrativeSG&A
2.19M1.78M1.78M2.69M2.79M2.29M2.49M3.74M2.52M2.03M1.87M3.75M1.84M2.11M2.11M2.33M1.94M2.12M2.59M2.54M
Operating ExpensesOpex
4.66M3.25M3.33M5.27M4.75M4.56M5.28M7.73M4.89M4.41M4.38M8.18M4.46M3.33M4.37M5.09M4.79M4.47M5.35M4.68M
Operating IncomeOp. Inc
-4.64M-3.21M-3.29M-5.18M-4.75M-4.56M-5.23M-7.73M-4.89M-4.41M-4.38M-8.18M-4.46M-3.33M-4.37M-5.09M-4.79M-4.47M-5.35M-4.68M
EBIT
-4.64M-3.21M-3.29M-5.18M-4.75M-4.56M-5.23M-7.73M-4.89M-4.41M-4.38M-8.18M-4.46M-3.33M-4.37M-5.09M-4.79M-4.47M-5.35M-4.68M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.12M0.08M0.11M0.05M0.04M0.04M0.08M0.08M0.09M0.06M
Other Non Operating IncomeOther Non Op Inc.
-0.03M-0.02M0.02M0.04M0.04M-0.20M-0.04M-0.06M0.08M-0.41M0.27M-0.04M-0.12M0.02M-0.10M-0.62M-0.03M-0.08M-0.17M0.05M
Net income details
EBT
-4.66M-3.23M-3.27M-5.08M-4.55M-4.60M-5.12M-7.66M-4.70M-5.00M-3.99M-8.14M-4.47M-5.78M-4.43M-5.67M-4.74M-7.64M-5.43M-4.57M
Tax ProvisionsTaxes
0.01M-0.01M0.00M0.01M0.00M0.08M0.02M0.03M0.02M0.01M0.02M0.00M0.01M0.50M0.10M0.14M0.55M-4.84M0.18M0.10M
Profit After TaxPAT
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-4.72M-4.01M-8.14M-4.49M-3.77M-4.53M-5.81M-5.28M-4.54M-5.61M-4.68M
Income from Non-Controlling InterestsInc. Minority
0.01M0.01M0.01M
Income from Continuing OperationsIncome (Continuing)
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-5.01M-4.01M-8.14M-4.49M-6.28M-4.53M-5.81M-5.28M-2.80M-5.61M-4.68M
Consolidated Net IncomeConsol Net Inc.
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-5.01M-4.01M-8.14M-4.49M-6.28M-4.53M-5.81M-5.28M-2.80M-5.61M-4.68M
Income towards Parent CompanyParent Net Inc
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-5.01M-4.01M-8.14M-4.49M-6.28M-4.53M-5.81M-5.28M-2.80M-5.61M-4.68M
Net Income towards Common StockholdersNet Income
-4.66M-3.22M-3.27M-5.09M-4.56M-4.67M-5.14M-7.69M-4.72M-5.01M-4.01M-8.14M-4.49M-6.28M-4.53M-5.81M-5.28M-2.80M-5.61M-4.68M
Additional items
EPS (Basic)
-0.39-0.32-0.28-0.43-0.38-0.39-0.43-0.62-0.37-0.39-0.22-0.42-0.17-0.27-0.16-0.19-0.15-0.08-0.13-0.11
EPS (Diluted)
-0.39-0.32-0.28-0.43-0.38-0.39-0.43-0.62-0.37-0.39-0.22-0.42-0.17-0.27-0.16-0.19-0.15-0.08-0.13-0.11
Shares Outstanding
11.88M10.17M11.88M11.88M11.88M11.88M11.94M12.39M12.70M13.01M17.98M19.22M26.53M22.88M28.69M30.34M35.00M32.97M42.23M42.88M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
11.88M10.17M11.88M11.88M11.88M11.88M11.94M12.39M12.70M13.01M17.98M19.22M26.53M22.88M28.69M30.34M35.00M32.97M42.23M42.88M
EBITDA
-4.64M-3.21M-3.29M-5.18M-4.75M-4.56M-5.23M-7.73M-4.89M-4.41M-4.38M-8.18M-4.46M-3.33M-4.37M-5.09M-4.79M-4.47M-5.35M-4.68M
Tax Rate
-0.110.26-0.05-0.18-0.09-1.70-0.33-0.35-0.46-0.29-0.50-0.01-0.25-8.74-2.28-2.49-11.6063.37-3.37-2.28